CXM is shining in my portfolio again. Bought @ 1.47 last week and its pushing the 2.00 range now. Results of their clinical trial should be out thursday, if all is well a 4.00pps is possible. At that point I sell and ride free shares.
CXM is shining in my portfolio again. Bought @ 1.47 last week and its pushing the 2.00 range now. Results of their clinical trial should be out thursday, if all is well a 4.00pps is possible. At that point I sell and ride free shares.
Looks like ASFX is making a rebound, gl to those who are still holding.
Pdmi is the one I wish I could have bought friday.
anyone long silver or gold?
SVM was one that I held @ 2.50 before it ran to current levels. I haven't delved into silver or gold so I'm never comfortable holding them. I am long on CPRK though.Originally Posted by Danny
Tony dude whats the deal with some military related stocks because i get the news on new stuff all the time
PIC TOO BIG
wtf just happened, the afternoon tank
Havent really found any that caught my attention as of yet but I'll definitely keep a look out.
Lessons learned today..
When those funds clear from a previous trade and that money is burning a hole in my pocket.. just sit on it instead of forcing a new position. Case in point, had about $1500 left over from profits in ASFX last thursday. The money was to go into a new position or CBAI at a really good entry point but I couldn't be patient. PDMI was on my radar but I overlooked it and bought CBAI at around .0090, now CBAI is at .0072 and PDMI went up 94% today.
In a nutshell, patience pays.
im glad asfx is going back up, but I sold it today and have moved everything over to biel and pdmi. Once BIEL sees fda approval I will be moving all of that into pdmi and ignt for the next month.
Hope to see .03-.10 in each one of those which will hopefully put me into the high 6-figure to 7-figure range. I can only hope lol
just curious, how many of you people trade with stock options rather than actual stocks?
I havent touched options yet, I think there are a couple here who do.
Ha remember that options seminar we went to like 4 years ago?
I went long with silver options the other day, decided to dabble my toes in that market..
What system are you using for your trading? And are you using that for your research or going elsewhere for info? I hardly use my Ameritrade account, but need to start focusing on improving it.
"Racing is life. Anything before or after is just waiting." - Steve McQueen
I go to various sources, yahoo finance, mystockbuddy, investorshub for level 2. I also use these to find new picks as well
If you can get in early on CXM tomorrow there might be a good 10%+ profit in it before the end of the day. Just a heads up..
The rest of my portfolio, stagnant today. A lot of waiting around for stuff to start moving and it just goes back to that thing of patience pays. A stock I held this past summer went up 132% today, so as much as I want to chase the movers I'm just going to stick to where I am.
A couple of noteworthy penny's here:
On 6/29/09, ADVENTRX Pharma (AMEX: ANX) ($0.12) stated that it has re-started the final manufacturing activities related to submitting an NDA for ANX-530 (vinorelbine emulsion). In addition, the Company will continue to evaluate the data from its recently completed bioequivalence study of ANX-514 (docetaxel emulsion) and plans to seek a meeting with the FDA to discuss the results. Both of these compounds represent novel emulsion formulations of currently marketed chemotherapy drugs. Navelbine and Taxotere are intravenously-injected chemotherapy drugs commonly used to treat solid tumors.
ANX believes the current formulations of these drugs have limitations that present opportunities for improvement and is developing novel ways to formulate the active ingredient underlying each of these drugs in a way that may improve their safety profiles without adversely affecting efficacy. On 8/12/09, ANX announced that the Company expects to complete and submit a New Drug Application (NDA) for ANX-530 to the FDA later this year.
On 8/24/09, Bioniche (TSX: BNC.TO) (OTC: BNHLF.PK) (US$0.47) announced that recruitment has been completed in its Phase 3 registration trial evaluating Urocidin in the treatment of non-muscle-invasive bladder cancer that is refractory (unresponsive) to the current standard immunotherapy - Bacillus Calmette-Gu�rin (BCG). The Data Monitoring Committee (DMC) held its ninth meeting regarding this clinical trial last week and has recommended that Bioniche "continue the trial unmodified until the next scheduled or triggered meeting." The next scheduled meeting of the Committee is scheduled to occur in October with a 10/31/09 estimated date for this entry for a possible update.
Data from the full cohort of 105 high-grade bladder cancer patients from this trial, coupled with additional safety information to be collected from a second clinical trial that is expected to start later this year, will be used to support regulatory submissions under the FDA's Accelerated Approval program. Bioniche is working with its new licensing partner, Endo Pharma (NASDAQ:ENDP) on setting up clinical trial sites for a second registration trial that will directly compare the efficacy and safety of Urocidin with BCG in the first-line treatment of non-muscle-invasive bladder cancer.
On 6/24/09, Cell Therapeutics (NASDAQ: CTIC) ($1.15) announced that it completed the submission of the New Drug Application (NDA) to the FDA for pixantrone to treat relapsed or refractory, aggressive non-Hodgkin's lymphoma (NHL). On 5/5/09, CTIC announced that pixantrone is available on a named-patient basis for use in Europe to treat patients with aggressive NHL that has either relapsed or is refractory to standard treatment options. On 9/5/09, CTIC announced that the FDA established a PDUFA action date of 4/23/10 (representing a standard, 10-month review designation) for pixantrone as a potential treatment for relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL).
CTIC estimates that pixantrone could be available to patients in the U.S. during early 2Q10 if approved by the FDA. On 9/16/09, CTIC announced 18-month follow-up data on Phase 3 study of pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkin's Lymphoma which Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard Chemotherapy and a 3.3-month Improvement over Standard Chemotherapy in Median Overall Survival. CTIC plans to submit these updated safety and efficacy data to the FDA as part of the 120-day update for its pending pixantrone NDA.
On 7/29/09, CTIC announced that it was notified by the European Medicines Agency (EMEA) that pixantrone is eligible to be submitted for a Marketing Authorization Application (MAA) through the EMEA's centralized procedure. CTIC will request a meeting with the EMEA to discuss the submission of the MAA for pixantrone to treat aggressive non-Hodgkin's lymphoma (NHL) in the EU member states. On 9/15/09, CTIC announced that it submitted a Pediatric Investigation Plan (PIP) to the European Medicines Agency (EMEA) as part of the required filing process for approval of pixantrone for treating relapsed or refractory, aggressive non-Hodgkins Lymphoma (NHL) in Europe.
CTIC initiated the process of obtaining marketing approval in Europe in July, 2009, for the treatment of relapsed or refractory aggressive Non-Hodgkin's Lymphoma (NHL). CTIC anticipates the formal Marketing Authorization Application (MAA) filing in 2010 (with an estimated 3/31/10 date for this entry) following approval of the pediatric investigation plan which was submitted to the EMEA earlier this month. CTI would be granted 10 year market exclusivity in Europe if the MAA is approved.[/I]
On 7/7/09, CEL-SCI Corp. (AMEX: CVM) ($1.38) provided the following updates in a letter to shareholders. The Company�s three business units include: (1) Vaccines/treatment: H1N1 (swine) and other influenza viruses, as well as a vaccine for rheumatoid arthritis; (2) Late-stage non-toxic cancer immunotherapy, Multikine, designed to make the first cancer treatment more successful; and (3) Unique contract manufacturing services using new manufacturing facility.
CVM recently completed its $22 million manufacturing facility, which is expected to be validated within the next three months (i.e. during fall 2009) for the manufacture of Multikine for the Company�s pending Phase III trial and subsequent sale if approved for marketing and stated that the validation of this facility is a critical step to starting the pivotal Phase 3 trial for Multikine. CVM stated that the Phase 3 study protocol was designed in consultation with the FDA and is expected to enroll about 800 patients to assess overall patient survival as the primary outcome. The Company also stated that the FDA has granted Multikine Orphan Drug status in the USA, and (if the Phase 3 study is successful) Multikine would be on course to become the recommended first-line treatment for head and neck cancer.
On 6/1/09, Chemgenex Pharma (OTC: CXSPY.PK) (ASX:CXS) (AUD$0.735) announced that the latest data from its pivotal study of omacetaxine in patients with T315I-positive chronic myeloid leukemia (CML). Data were presented from 66 patients: 40 in chronic phase, 16 in accelerated phase and 10 in blast phase. Highlights of the data were: (1) Chronic phase patients: Complete hematologic response (CHR) rate of 85% with a median response duration 8.9 months; Major cytogenetic response (MCyR) rate of 15% with a median response duration 6.1 months. (2) Accelerated phase patients: CHR rate of 31% with a median duration 4.1 months' MCyR rate of 6% with a median response duration 1.8 months. (3) Blast phase patients: CHR rate of 20% with a median duration 3.3 months. Investigators reported that omacetaxine is generally well tolerated, and that the most common side effect is reversible and transient myelosuppression.
On 9/9/09, ChemGenex announced that it completed the submission of its New Drug Application (NDA) to the FDA for OMAPRO (omacetaxine mepesuccinate) in the treatment of patients with chronic myeloid leukemia (CML) who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation. OMAPRO has received Orphan Drug designation in the U.S. and in the European Union, and has received fast track status from the FDA. If the FDA designates a priority (six-month) review, the estimated decision date is 3/9/10.
On 8/7/09, Cytomedix (AMEX:GTF) ($0.56) announced the filing of a 510(k) pre-market notification with the FDA seeking marketing clearance to market its AutoloGel Platelet Separation System for use in orthopedics. The application includes the option of mixing of platelet-rich plasma (PRP) derived by the AutoloGel System with auto-graft and/or allograft bone, intra-operatively, prior to application to an orthopedic site as deemed necessary by clinical use requirements. The AutoloGel System is already cleared by the FDA for use on a variety of exuding wounds. The Company is pursuing a multi-faceted strategy to penetrate the chronic wound market with its AutoloGel System. The 12/7/09 date for this entry is a four-month review estimate since the FDA does not issue decision deadlines for medical device submissions.
As of its corporate presentation dated 8/21/09, Derma Sciences (DSCI.OB) ($0.70) reported that it continues to move forward with a Phase 2 clinical trial of DSC127, which has the potential to be only the second approved drug on the market for accelerated wound healing. The Company stated that 33% of patients are currently enrolled in a Phase 2 diabetic foot ulcer study. DSC127 (which is an analog of a naturally occurring peptide called Angiotensin that has been shown to increase keratinocyte proliferation, increase extracellular matrix production, and increase vascularization) was licensed from the University of Southern California during 4Q07 and patient enrollment for a Phase 2 study began during 4Q08.
This study of 75 patients will look at the percentage of diabetic ulcers completely healed over a 12-week period in addition to other outcomes. Histological examination reveals that DSC127 accelerates collagen deposition six-fold and the patented amino acid peptide optimizes the wound healing capabilities of Angiotensin while removing all blood pressure effects of the compound. The Phase II results for the DSC127 Diabetic Ulcer trial are scheduled for release during early 3Q10, with an estimated date for this entry of 7/31/10.
Discovery Labs (NASDAQ: DSCO) ($1.07) held a teleconference on 9/29/09 with the FDA which established an approach to potentially resolve the remaining primary issue that Discovery Labs must address to gain U.S. marketing approval of Surfaxin (lucinactant) for the prevention of Respiratory Distress Syndrome (RDS) in premature infants. The meeting focused on Discovery Labs' plans regarding optimization and final method validation of its fetal rabbit Biological Activity Test (BAT, a quality control and stability release test) and a proposed limited Surfaxin clinical trial design, which would simultaneously employ the newly-optimized BAT. At the meeting, the FDA indicated that the Company�s proposed program to optimize and validate the BAT is reasonable.
The program is intended, among other things, to confirm that the BAT can adequately distinguish change in Surfaxin biological activity over time. As a result of the meeting, DSCO believes that it has reached an understanding with the FDA and is confident that it will be able to optimize the BAT to the satisfaction of the FDA. Discovery Labs intends to employ the optimized BAT in conjunction with all of the Company�s KL4 surfactant pipeline programs, including the potential limited Surfaxin clinical trial. DSCO expects to finalize a protocol and anticipates submitting it to the FDA in mid 4Q09 (with an estimated date for this entry of 11/15/09 based on this guidance).
Pretty uneventful. My gold is up a hair, while my silver and silver options netted zero for the day. I think silver may be building a base here and hopefully will continue upwards soon.
Maybe tomorrow wont be quite so boring, in a good way i hope.
October, 14th
8:30 AM Export Prices ex-ag. Sep
8:30 AM Import Prices ex-oil Sep
8:30 AM Retail Sales Sep
8:30 AM Retail Sales ex-auto Sep
10:00 AM Business Inventories Aug
2:00 PM FOMC Minutes Sep
Expecting good things on my side as well, GL to you tomorrow Danny.
Thanks tony, what plays are you goin for tomorrow?
whoa just checked silver. Hong kong market already has silver up to 17.98! Lets hope it keeps going through London and on to NewYork!
I think tomorrow may be interesting for everyone. Inless your long USD of course
I'm in heavy on pdmi now. A few million shares there, and it should easily see .03-.05 in the next month.
If you have extra cash tomorrow, it should see a dip which would be a very good entry point after it ran about 95% 2 days ago and around 20% today.
How is it looking this morning? I'm expecting phase II results from cxm but I may go long on this one since they're expecting some good things in the long term.whoa just checked silver. Hong kong market already has silver up to 17.98! Lets hope it keeps going through London and on to NewYork!
I think tomorrow may be interesting for everyone. Inless your long USD of course
better than expected retail sales this am. hope this helps the market along.
Silver and gold didnt do so well this morning, back down to NY levels of yesterday.
What's with the drop in CXM? It seems like they released good news, is this just a normal pattern before the conference call/webcast this afternoon?
Sorry if I'm asking noob questions, I'm just kind of starting to dip my feet into this stuff.
Last edited by MarcTheNarc; 10-14-2009 at 10:29 AM.
WTB: B13 SE-R, PM me
Not a noob question, this is actually something I explained to some seasoned investors. With stocks like CXM where a big date is anticipated a lot of short term investors play the run up. The idea is buy on the run up, sell on the news. And rightfully so, had you bought last week you wouldve sold with a 40 percent profit. So what you are seeing today is a massive selloff on the news which every investor I talked to said they were going to do anyway, no big suprises. BDSI is another one that did this.
Here's the thing, I form my strategy when I bought, I wouldn't sell short for anything lower than 3 dollars, otherwise my strategy is long term, this is only phase II results released today. With these good results the company moves forward to phase III then fda, learning what I have since I've been investing I'm very comfortable with my investment, the price drop and the future of this company. Patience pays and once the short term investors are shaken off this stock will start moving again.
I see. That's actually a simple principle, just not something I would have thought of. It does make sense though, I appreciate the info.
WTB: B13 SE-R, PM me
Any time, with CXM I did think about selling above 2, wait for the selloff and buy back in to add about 25 percent more shares but I didn't want to risk missing a run. Either way I doubled my shares @ 1.42, a nice point to buy at.
I did learn a few thins on this play, one I've learned how to control emotion. Months ago I wouldve sold today and after missing opportunities due to panicking I feel like I got a good hold on that. I've also learned if you're going to sell on the news, sell a day or two before not the day of.
Next on my list is CTYX, big things to come in the future.
ya hoes
essentially the efficient-market hypothesis at work.
Selling on news is common and so is selling into a run. Normally they happen together.
Some food for thought, and again i dont know the stock. But with all the better than expected PRs the last day or two could have raised investor expectation of today's PR, when the PR came out investors found that it was inline with their last week expectations they were forced and was not as good as their current expectations then the stock price will decline. Then you throw in emotional sell offs, profit takers, and people trying to secure profit or minimize losses, and a few bad rumors around the message boards and you have the workings for a shatty day
Just some food for thought presented to you in a probably poorly structured paragraph thats difficult to read
Check this out. No bueno for the dollar guys.
I've thought about that, the expected PR already factored into the price. Either way I am sticking with it, too much of an upside for me to sell right now.essentially the efficient-market hypothesis at work.
Selling on news is common and so is selling into a run. Normally they happen together.
Some food for thought, and again i dont know the stock. But with all the better than expected PRs the last day or two could have raised investor expectation of today's PR, when the PR came out investors found that it was inline with their last week expectations they were forced and was not as good as their current expectations then the stock price will decline. Then you throw in emotional sell offs, profit takers, and people trying to secure profit or minimize losses, and a few bad rumors around the message boards and you have the workings for a shatty day
Just some food for thought presented to you in a probably poorly structured paragraph thats difficult to read
On a side note, anyone familiar with SNDY? I put it on a watch list yesterday and I dont know where I researched it at but it jumped 100% today. Glad the market has made news with its movement today.
BZCN, this is one we mentioned earlier in this thread.. is there life in this stock now? Ironic that I sold my last 350k shares this morning.
Danny these are shitty pics I took with my phone when I was in Frankfurt. The giant Euro sign (the one in your avatar) and the stock exchange.
/threadjack
Haha, thats bad ass! How was it there, i bet its amazing. I wanna go on a trip so bad.
How bout lets find a stock that will fund (or partially fund) a trip to the euros? IA investors club trip haha. Thanks for the pics man!
Posting Permissions
Reply With Quote
.
